Liposomal amphotericin B associated with severe hyperphosphatemia.
We report 4 patients who developed hyperphosphatemia while receiving liposomal amphotericin B to treat an invasive fungal infection. Resolution of the hyperphosphatemia occurred after transition to amphotericin B lipid complex. This phenomenon may occur more commonly in patients with mild to moderate renal insufficiency.
Sutherland
Scott M
SM
Division of Pediatric Nephrology, Department of Pediatrics, Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA, USA. suthersm@stanford.edu
Hong
David K
DK
Balagtas
Jay
J
Gutierrez
Kathleen
K
Dvorak
Christopher C
CC
Sarwal
Minnie
M
D000293:Adolescent; D000666:Amphotericin B / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D004338:Drug Combinations; D005260:Female; D006801:Humans; D054559:Hyperphosphatemia; D008297:Male; D009181:Mycoses / Q000188:drug therapy*; D010713:Phosphatidylcholines / Q000627:therapeutic use; D010715:Phosphatidylglycerols / Q000627:therapeutic use; D051437:Renal Insufficiency / Q000150:complications
D004338:Drug Combinations; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B